<DOC>
	<DOCNO>NCT01028716</DOCNO>
	<brief_summary>This phase II trial study well donor peripheral blood stem cell ( PBSC ) transplant work treat patient hematologic malignancy . Cyclophosphamide add tacrolimus mycophenolate mofetil safe effective prevent severe graft-versus-host disease ( GVHD ) patient hematologic malignancy undergo transplantation bone marrow half-matched ( haploidentical ) donor . This approach extend transplant option patient match related unrelated donor , especially patient ethnic minority group . The graft contain cell donor 's immune system potentially recognize destroy patient 's cancer cell ( graft-versus-tumor effect ) . Rejection donor 's cell patient 's immune system prevent give low dos chemotherapy ( fludarabine phosphate cyclophosphamide ) total-body irradiation transplant . Patients experience low blood cell count transplant . Using stem cell immune cell collect donor 's circulate blood may result quick recovery blood count may effective treat patient 's disease use bone marrow .</brief_summary>
	<brief_title>Donor Peripheral Blood Stem Cell Transplant Treating Patients With Hematologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To demonstrate use PBSC place marrow source lymphocytes stem cell nonmyeloablative transplant relate , haploidentical donor result unacceptable rate high-grade acute chronic GVHD , non-relapse mortality relapse compare historical data nonmyeloablative transplant unrelated donor . SECONDARY OBJECTIVES : I . Estimates rate neutrophil platelet recovery , number red blood cell ( RBC ) platelet transfusion , incidence graft failure , transplant-related toxicity , disease-free survival overall survival . OUTLINE : Patients receive fludarabine intravenously ( IV ) 30-60 minute daily day -6 -2 cyclophosphamide IV 1-2 hour day -6 , -5 , 3-4 . Patients undergo total-body irradiation day -1 . Patients undergo donor peripheral blood stem cell transplant day 0 . Patients receive tacrolimus IV daily orally ( PO ) twice daily ( BID ) day 5-180 ( may continue active GVHD present ) , mycophenolate mofetil IV PO thrice daily ( TID ) day 5-35 ( may continue GVHD present ) , filgrastim IV begin day 5 absolute neutrophil count ( ANC ) &gt; = 1,000/mm^3 three consecutive day . Treatment continue absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Biphenotypic , Acute</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Molecular base human leukocyte antigen ( HLA ) type perform HLAA , B , Cw , DRB1 DQB1 locus resolution adequate establish haploidentity ; minimum match 5/10 require ; unrelated donor search require patient eligible protocol clinical situation dictate urgent transplant ; clinical urgency define 68 week referral lowlikelihood find match , unrelated donor Acute leukemia ( include T lymphoblastic lymphoma ) ; remission define &lt; 5 % blast morphological characteristic acute leukemia ( e.g. , Auer rod ) bone marrow &gt; 20 % cellularity , peripheral blood count show ANC &gt; 1000/ul , include patient complete remission incomplete platelet recovery ( CRp ) ; marrow &lt; 20 % cellularity due treatment related cytotoxicity , still &lt; 5 % blast , exception may make include patient principal investigator ( PI ) discretion Acute lymphoblastic leukemia high risk first complete remission ( CR1 ) define least one following : Adverse cytogenetics include limited ( 9 ; 22 ) , ( 1 ; 19 ) , ( 4 ; 11 ) , mixed lineage leukemia ( MLL ) rearrangements White blood cell count &gt; 30,000/mcL Patients 30 year age Time complete remission &gt; 4 week Presence extramedullary disease Minimal residual disease Other risk factor determine patient 's attend physician high risk feature require transplantation Acute myelogenous leukemia high risk CR1 define least one following : Greater 1 cycle induction therapy require achieve remission Preceding myelodysplastic syndrome ( MDS ) Presence fmslike tyrosine kinase receptor3 ( Flt3 ) abnormalities FrenchAmericanBritish ( FAB ) M6 M7 leukemia , Adverse cytogenetics overall survival : Those associated MDS Complex karyotype ( &gt; = 3 abnormality ) ; Any following : inv ( 3 ) ( 3 ; 3 ) , ( 6 ; 9 ) , ( 6 ; 11 ) , + 8 [ alone abnormalities except ( 8 ; 21 ) , ( 9 ; 11 ) , inv ( 16 ) ( 16 ; 16 ) ] , ( 11 ; 19 ) ( q23 ; p13.1 ) ] Other risk factor determine patient 's attend physician high risk feature require transplantation Acute leukemias second ( 2nd ) subsequent remission Biphenotypic/undifferentiated leukemia first ( 1st ) subsequent complete remission ( CR ) Highrisk MDS statuspost cytotoxic chemotherapy Burkitt 's lymphoma : second subsequent CR Chemotherapysensitive ( least stable disease ) large cell , mantle cell Hodgkin 's lymphoma fail least 1 prior regimen multiagent chemotherapy ineligible autologous transplant Marginal zone Bcell lymphoma follicular lymphoma progress least two prior therapy ( exclude single agent Rituxan ) Multiple myeloma ( MM ) stage II III patient progress initial response chemotherapy autologous hematopoietic stem cell transplantation ( HSCT ) MM patient refractory disease may benefit tandem autologousnonmyeloablative allogeneic transplant Left ventricular ejection fraction rest must &gt; = 35 % Bilirubin = &lt; 2.5 mg/dL Alanine aminotransferase ( ALT ) &lt; 5 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) &lt; 5 x ULN Alkaline phosphatase &lt; 5 x ULN Serum creatinine within normal range age , serum creatinine outside normal range age , renal function ( creatinine clearance glomerular filtration rate [ GFR ] ) &gt; 40 mL/min/1.73m^2 Forced expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) , diffusion capacity carbon monoxide ( DLCO ) ( diffusion capacity ) &gt; = 40 % predict ( correct hemoglobin ) ; unable perform pulmonary function test , oxygen ( O2 ) saturation &gt; 92 % room air Karnofsky/Lansky score &gt; = 60 % Patients receive prior allogeneic HSCT either reject graft become tolerant graft active GVHD require immunosuppressive therapy Patients undergo standard pretransplant workup dictate standard practice guideline result may use screen study DONOR : Donors must HLAhaploidentical firstdegree relatives patient ; eligible donor include biological parent , sibling , child , halfsiblings DONOR : Age &gt; = 12 year DONOR : Weight &gt; = 40 kg DONOR : Ability donor &lt; 18 year age undergo apheresis without use vascular access device ; vein check must perform verified apheresis nurse prior arrival Seattle Cancer Care Alliance ( SCCA ) DONOR : Donors must meet selection criterion define Foundation Accreditation Cell Therapy ( FACT ) screen per American Association Blood Banks ( AABB ) guideline HLAmatched single allelemismatched donor able donate Pregnancy breastfeed Current uncontrolled bacterial , viral fungal infection ( currently take medication evidence progression clinical symptom radiologic finding ) Patients primary idiopathic myelofibrosis DONOR : Positive antidonor HLA antibody</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>